THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Health Issues HCR
S. 2333, Pandemic and All-Hazards Preparedness and Response Act. H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREG D'ANGELO | — |
| DONALD KENT | — |
| MARY BETH SAVARY TAYLOR | — |
Aerospace AER
FAA reauthorization - increasing access to naloxone.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Aviation/Airlines/Airports AVI
Increasing access to Naloxone.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.